Lehrstuhl für Haut- und Geschlechtskrankheiten


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors (2018) Sirtl S, Knoll G, Dieu Thuy Trinh , Lang I, Siegmund D, Gross S, Schuler-Thurner B, et al. Journal article From relative to absolute Treatment Goals - Correlation of PASI 90 and PASI <=2 in three clinical Studies with Secukinumab (2018) Reich K, Bachhuber T, Melzer N, Sieder C, Sticherling M Conference contribution Can checkpoint inhibitor therapy improve response to chemotherapy? (2018) Kirchberger MC, Schilling B, Haferkamp S, Boßerhoff AK, Schuler G, Heinzerling L Journal article The p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris-Analysis of Four Different Ethnic Cohorts (2018) Recke A, Konitzer S, Lemcke S, Freitag M, Sommer NM, Abdelhady M, Amoli MM, et al. Journal article The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma (2018) Simon B, Wiesinger M, Maerz J, Wistuba-Hamprecht K, Weide B, Schuler-Thurner B, Schuler G, et al. Journal article The simultaneous siRNA-mediated downregulation of PD-1 and CTLA-4 to improve CAR-T cell immunotherapy of melanoma (2018) Simon B, Harrer D, Schuler-Thurner B, Dörrie J, Schaft N, Schuler G, Uslu U Conference contribution Understanding microRNA-mediated immunogenicity of dendritic cells using an integrative approach (2018) Lai X, Dreyer F, Jaitly T, Cantone M, Gerer KF, Schuler G, Dörrie J, et al. Conference contribution Managing toxicities of immunotherapies - a side effect register for rare and severe side effects of checkpoint Inhibitor therapy (2018) Heinzerling L, Schuler G Conference contribution Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome (2018) Moreira A, Kirchberger MC, Toussaint F, Erdmann M, Schuler G, Heinzerling L Journal article Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients (2018) Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, et al. Journal article